Overall rank by patents
#24,295
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Entasis Therapeutics, Inc.
USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
11
Total patents granted
4
CPC technology areas
15.3
Avg claims per patent
-62%
5-year filing velocity
The verdict
Entasis holds 11 US patents across 4 technology areas, rank #24,295 of 50,000 tracked assignees.
- #24,295
- of 50,000 US assignees by volume
- Top 84%
- by Innovation Score (24.8/100)
- 15.3
- avg claims per patent
- -62%
- filing velocity, last 5 yrs
Portfolio overview
Entasis Therapeutics, Inc. has been granted 11 US utility patents between 2015 and 2025, placing Entasis Therapeutics, Inc. at rank #24,295 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.3 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Entasis Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Entasis sits between Enerdel, Inc. (11 patents, rank #24,291) and Esdec B.v. (11 patents, rank #24,299) - the closest US assignees by grant volume. The composite Innovation Score of 24.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 3 grants, compared with 8 in the 2015–2019 window, a -62% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Entasis Therapeutics, Inc.'s 15.3 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Entasis Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Entasis's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Enerdel
EnerDel, Inc.
11 patents
- Energysolutions
EnergySolutions, Inc.
11 patents
- Enfabrica
Enfabrica Corporation
11 patents
- Ennis-flint
Ennis-Flint, Inc.
11 patents
- Eppendorf Himac
Eppendorf Himac Technologies Co., Ltd.
11 patents
- Erowa
Erowa AG
11 patents
- Erwin Junker Masc…
Erwin Junker Maschinenfabrik GmbH
11 patents
- Esdec B V
Esdec B.V.
11 patents
- Entasis Therapeut… ◀
Entasis Therapeutics, Inc.
11 patents
What this shows Entasis holds 11 patents at rank #24,295, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Entasis's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
25 Top 84% higher than 16% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2016 | 1 | 9.1% |
| 2017 | 3 | 27.3% |
| 2018 | 1 | 9.1% |
| 2019 | 2 | 18.2% |
| 2020 | 1 | 9.1% |
| 2021 | 1 | 9.1% |
| 2025 | 1 | 9.1% |
Which technologies does Entasis Therapeutics, Inc. patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Entasis Therapeutics, Inc. hold?
Entasis Therapeutics, Inc. holds 11 US granted patents filed between 2015 and 2025, spanning 4 technology areas.
What is Entasis Therapeutics, Inc.'s Innovation Score?
Entasis Therapeutics, Inc. has an Innovation Score of 24.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Entasis Therapeutics, Inc. focus on?
Entasis Therapeutics, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 11 patents. The company has filed patents in 4 CPC subclasses total.
Is Entasis Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Entasis Therapeutics, Inc.'s recent filing velocity is -62% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Entasis Therapeutics, Inc.'s patents?
Entasis Therapeutics, Inc.'s patents average 15.3 claims each. This falls within the standard range, providing solid legal coverage.
How is the Entasis Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Entasis's 11 grants land it in the top 84% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Entasis ranks #24,295 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.